Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center

Bülent Bozdogan, Duygu Esel, Cynthia Whitener, Frederick A. Browne, Peter C. Appelbaum

Research output: Contribution to journalArticle

179 Citations (Scopus)

Abstract

Staphylococcus aureus strain HMC3 isolated at the Hershey Medical Center, was resistant to vancomycin (VRSA) through the presence of the vanA resistance gene; it also contained mecA, erm(A), erm(B), tet(K) and aac(6′)-aph(2″), conferring resistance to licensed β-lactams, macrolides, tetracycline and aminoglycosides. HMC3 also had alterations in GyrA and GrlB and was resistant to available quinolones. Experimental drugs with low MICs (<2 mg/L) for VRSA HMC3 included cephalosporins BAL9141 and RWJ-54428; glycopeptides oritavancin and dalbavancin; the lipopeptide daptomycin; the glycolipodepsipeptide ramoplanin; new fluoroquinolones WCK 771 A, WCK 1153, DK-507k and sitafloxacin; and the DNA nanobinder GS02-02. These agents were all bactericidal as were trimethoprim/sulfamethoxazole and telcoplanin (MIC 4 mg/L). Oxazolidinones linezolid and ranbezolid; the injectable streptogramin quinupristin/dalfopristin; DNA nanobinders GS2-10547 and GS02-104; peptide deformylase inhibitors NVP-PDF713 and GS02-12; tetracycline derivative tigecycline; the antifolate iclaprim; mupirocin and fusidic acid were all active in vitro but bacteriostatic.

Original languageEnglish (US)
Pages (from-to)864-868
Number of pages5
JournalJournal of Antimicrobial Chemotherapy
Volume52
Issue number5
DOIs
StatePublished - Nov 1 2003

Fingerprint

Linezolid
peptide deformylase
Vancomycin
ramoplanin
Tetracycline
oritavancin
Staphylococcus aureus
Streptogramins
Mupirocin
Fusidic Acid
Daptomycin
Oxazolidinones
Lipopeptides
Folic Acid Antagonists
Lactams
Glycopeptides
DNA
Quinolones
Fluoroquinolones
Macrolides

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Bozdogan, Bülent ; Esel, Duygu ; Whitener, Cynthia ; Browne, Frederick A. ; Appelbaum, Peter C. / Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. In: Journal of Antimicrobial Chemotherapy. 2003 ; Vol. 52, No. 5. pp. 864-868.
@article{5391ba659134457ea09216a60e82bbf0,
title = "Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center",
abstract = "Staphylococcus aureus strain HMC3 isolated at the Hershey Medical Center, was resistant to vancomycin (VRSA) through the presence of the vanA resistance gene; it also contained mecA, erm(A), erm(B), tet(K) and aac(6′)-aph(2″), conferring resistance to licensed β-lactams, macrolides, tetracycline and aminoglycosides. HMC3 also had alterations in GyrA and GrlB and was resistant to available quinolones. Experimental drugs with low MICs (<2 mg/L) for VRSA HMC3 included cephalosporins BAL9141 and RWJ-54428; glycopeptides oritavancin and dalbavancin; the lipopeptide daptomycin; the glycolipodepsipeptide ramoplanin; new fluoroquinolones WCK 771 A, WCK 1153, DK-507k and sitafloxacin; and the DNA nanobinder GS02-02. These agents were all bactericidal as were trimethoprim/sulfamethoxazole and telcoplanin (MIC 4 mg/L). Oxazolidinones linezolid and ranbezolid; the injectable streptogramin quinupristin/dalfopristin; DNA nanobinders GS2-10547 and GS02-104; peptide deformylase inhibitors NVP-PDF713 and GS02-12; tetracycline derivative tigecycline; the antifolate iclaprim; mupirocin and fusidic acid were all active in vitro but bacteriostatic.",
author = "B{\"u}lent Bozdogan and Duygu Esel and Cynthia Whitener and Browne, {Frederick A.} and Appelbaum, {Peter C.}",
year = "2003",
month = "11",
day = "1",
doi = "10.1093/jac/dkg457",
language = "English (US)",
volume = "52",
pages = "864--868",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "5",

}

Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. / Bozdogan, Bülent; Esel, Duygu; Whitener, Cynthia; Browne, Frederick A.; Appelbaum, Peter C.

In: Journal of Antimicrobial Chemotherapy, Vol. 52, No. 5, 01.11.2003, p. 864-868.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center

AU - Bozdogan, Bülent

AU - Esel, Duygu

AU - Whitener, Cynthia

AU - Browne, Frederick A.

AU - Appelbaum, Peter C.

PY - 2003/11/1

Y1 - 2003/11/1

N2 - Staphylococcus aureus strain HMC3 isolated at the Hershey Medical Center, was resistant to vancomycin (VRSA) through the presence of the vanA resistance gene; it also contained mecA, erm(A), erm(B), tet(K) and aac(6′)-aph(2″), conferring resistance to licensed β-lactams, macrolides, tetracycline and aminoglycosides. HMC3 also had alterations in GyrA and GrlB and was resistant to available quinolones. Experimental drugs with low MICs (<2 mg/L) for VRSA HMC3 included cephalosporins BAL9141 and RWJ-54428; glycopeptides oritavancin and dalbavancin; the lipopeptide daptomycin; the glycolipodepsipeptide ramoplanin; new fluoroquinolones WCK 771 A, WCK 1153, DK-507k and sitafloxacin; and the DNA nanobinder GS02-02. These agents were all bactericidal as were trimethoprim/sulfamethoxazole and telcoplanin (MIC 4 mg/L). Oxazolidinones linezolid and ranbezolid; the injectable streptogramin quinupristin/dalfopristin; DNA nanobinders GS2-10547 and GS02-104; peptide deformylase inhibitors NVP-PDF713 and GS02-12; tetracycline derivative tigecycline; the antifolate iclaprim; mupirocin and fusidic acid were all active in vitro but bacteriostatic.

AB - Staphylococcus aureus strain HMC3 isolated at the Hershey Medical Center, was resistant to vancomycin (VRSA) through the presence of the vanA resistance gene; it also contained mecA, erm(A), erm(B), tet(K) and aac(6′)-aph(2″), conferring resistance to licensed β-lactams, macrolides, tetracycline and aminoglycosides. HMC3 also had alterations in GyrA and GrlB and was resistant to available quinolones. Experimental drugs with low MICs (<2 mg/L) for VRSA HMC3 included cephalosporins BAL9141 and RWJ-54428; glycopeptides oritavancin and dalbavancin; the lipopeptide daptomycin; the glycolipodepsipeptide ramoplanin; new fluoroquinolones WCK 771 A, WCK 1153, DK-507k and sitafloxacin; and the DNA nanobinder GS02-02. These agents were all bactericidal as were trimethoprim/sulfamethoxazole and telcoplanin (MIC 4 mg/L). Oxazolidinones linezolid and ranbezolid; the injectable streptogramin quinupristin/dalfopristin; DNA nanobinders GS2-10547 and GS02-104; peptide deformylase inhibitors NVP-PDF713 and GS02-12; tetracycline derivative tigecycline; the antifolate iclaprim; mupirocin and fusidic acid were all active in vitro but bacteriostatic.

UR - http://www.scopus.com/inward/record.url?scp=0242437814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242437814&partnerID=8YFLogxK

U2 - 10.1093/jac/dkg457

DO - 10.1093/jac/dkg457

M3 - Article

C2 - 14563898

AN - SCOPUS:0242437814

VL - 52

SP - 864

EP - 868

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 5

ER -